Last month in New Orleans the Digestive Disease Week (DDW) convention was held. Gastroenterologists nationwide attended DDW to share insight about the ever evolving practice of treating gastrointestinal diseases and research findings that could be potential game-changers. As they say, it was a place for gastroenterologists to turn science into medicine.
The Wall Street Journal reported that during DDW pharmaceutical company Sucampo Pharmaceuticals presented the results of their phase 2 clinical trial of cobiprostone, an investigational drug, for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). Byron Cryer, M.D., the principal investigator in the trial said, “These data demonstrate that cobiprostone may be a new strategy for prevention of gastrointestinal injury in patients receiving NSAIDs. If successfully developed for this indication, cobiprostone would protect a large number of patients.”